ZA200105009B - Skin care compositions containing cis-9, trans-11 linoleic acid. - Google Patents
Skin care compositions containing cis-9, trans-11 linoleic acid. Download PDFInfo
- Publication number
- ZA200105009B ZA200105009B ZA200105009A ZA200105009A ZA200105009B ZA 200105009 B ZA200105009 B ZA 200105009B ZA 200105009 A ZA200105009 A ZA 200105009A ZA 200105009 A ZA200105009 A ZA 200105009A ZA 200105009 B ZA200105009 B ZA 200105009B
- Authority
- ZA
- South Africa
- Prior art keywords
- skin
- cla
- linoleic acid
- conjugated linoleic
- isomer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 71
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims description 20
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 title description 4
- 235000020778 linoleic acid Nutrition 0.000 title description 4
- 238000000034 method Methods 0.000 claims description 27
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims description 21
- 239000002537 cosmetic Substances 0.000 claims description 18
- 206010051246 Photodermatosis Diseases 0.000 claims description 16
- 229940108924 conjugated linoleic acid Drugs 0.000 claims description 16
- 230000000699 topical effect Effects 0.000 claims description 16
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 238000007665 sagging Methods 0.000 claims description 8
- 206010013786 Dry skin Diseases 0.000 claims description 6
- 230000037336 dry skin Effects 0.000 claims description 6
- 230000037307 sensitive skin Effects 0.000 claims description 6
- JBYXPOFIGCOSSB-UQGDGPGGSA-N rumenic acid Chemical compound CCCCCC\C=C/C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-UQGDGPGGSA-N 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 description 81
- 102000004237 Decorin Human genes 0.000 description 23
- 108090000738 Decorin Proteins 0.000 description 23
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 17
- 230000002500 effect on skin Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 210000002510 keratinocyte Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 229930002330 retinoic acid Natural products 0.000 description 13
- 229960001727 tretinoin Drugs 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000003656 tris buffered saline Substances 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000003712 anti-aging effect Effects 0.000 description 8
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 210000000245 forearm Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- -1 phosphoesters) Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010050808 Procollagen Proteins 0.000 description 5
- 241000030538 Thecla Species 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008845 photoaging Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 108060008539 Transglutaminase Proteins 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102000003601 transglutaminase Human genes 0.000 description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 241000235403 Rhizomucor miehei Species 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008436 biogenesis Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000199 molecular distillation Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- MGYUQZIGNZFZJS-KTKRTIGZSA-N 2-[2-[(z)-octadec-9-enoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCO MGYUQZIGNZFZJS-KTKRTIGZSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 101100006825 Cochliobolus lunatus clz2 gene Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000159512 Geotrichum Species 0.000 description 1
- 244000168141 Geotrichum candidum Species 0.000 description 1
- 235000017388 Geotrichum candidum Nutrition 0.000 description 1
- 101001000206 Homo sapiens Decorin Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical class CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Chemical class 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 102000045840 human DCN Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9828379.9A GB9828379D0 (en) | 1998-12-22 | 1998-12-22 | Skin care composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200105009B true ZA200105009B (en) | 2002-06-19 |
Family
ID=10844842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200105009A ZA200105009B (en) | 1998-12-22 | 2001-06-19 | Skin care compositions containing cis-9, trans-11 linoleic acid. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6287553B1 (pt) |
| EP (1) | EP1140003B2 (pt) |
| JP (1) | JP4460169B2 (pt) |
| CN (1) | CN1217651C (pt) |
| AR (1) | AR021949A1 (pt) |
| AT (1) | ATE482749T1 (pt) |
| AU (1) | AU767130B2 (pt) |
| BR (1) | BR9916450B1 (pt) |
| CA (1) | CA2355633C (pt) |
| CZ (1) | CZ302773B6 (pt) |
| DE (1) | DE69942807D1 (pt) |
| ES (1) | ES2350900T5 (pt) |
| GB (1) | GB9828379D0 (pt) |
| MX (1) | MXPA01006455A (pt) |
| PL (1) | PL200949B1 (pt) |
| RU (1) | RU2253443C2 (pt) |
| TW (1) | TWI250025B (pt) |
| WO (1) | WO2000037040A1 (pt) |
| ZA (1) | ZA200105009B (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136985A (en) * | 1997-12-23 | 2000-10-24 | Dcv, Inc. | CLA esters and uses thereof |
| US6132582A (en) | 1998-09-14 | 2000-10-17 | The Perkin-Elmer Corporation | Sample handling system for a multi-channel capillary electrophoresis device |
| US6296861B1 (en) * | 1999-05-03 | 2001-10-02 | Nicholas V. Perricone | Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters |
| WO2001003688A2 (en) * | 1999-07-09 | 2001-01-18 | Pharmacia Corporation | Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| GB9918028D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
| ITMI991894A1 (it) * | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
| NO310176B1 (no) * | 2000-11-13 | 2001-06-05 | Wadlund As | Sammensetning for hud som inneholder kitosan-konjugert CLA og kitosankonjugert vitamin A eller et <beta>-cyklodekstrin-konjugertvitamin A samt fremgangsmåte for fremstilling og anvendelse avdenne |
| EP1397041A4 (en) * | 2001-05-31 | 2004-11-17 | Wisconsin Alumni Res Found | COMPOSITIONS CONTAINING CONJUGATED NONADECADIC ACID |
| US20030059450A1 (en) | 2001-09-24 | 2003-03-27 | Maibach Howard I. | Method and topical formulation for treating skin conditions associated with aging |
| US6677470B2 (en) * | 2001-11-20 | 2004-01-13 | Natural Asa | Functional acylglycerides |
| TW200407172A (en) | 2002-10-17 | 2004-05-16 | Unilever Nv | Scalp treatment |
| US7074418B2 (en) * | 2002-11-18 | 2006-07-11 | Changaris David G | Conjugated fatty acid based emulsion and methods for preparing and using same |
| AU2004251774A1 (en) * | 2003-06-25 | 2005-01-06 | Charles Erwin | Chemical combination and method for increasing delivery of coenzyme Q 10 |
| US7193096B2 (en) * | 2003-07-01 | 2007-03-20 | Loders Croklaan Usa Llc | Process for producing a conjugated di- or poly-unsaturated fatty acid of 12 to 24 carbon atoms or salt or ester thereof |
| JP2005247826A (ja) * | 2004-02-04 | 2005-09-15 | Kose Corp | デコリン産生促進剤及びそれを含有する皮膚外用剤 |
| US20050186231A1 (en) * | 2004-02-19 | 2005-08-25 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Stabilization with substituted ureas against color degradation of personal care products |
| WO2006037922A1 (fr) * | 2004-10-04 | 2006-04-13 | L'oreal | Composition cosmetique et/ou dermatologique pour peaux sensibles |
| FR2889057B1 (fr) * | 2005-08-01 | 2008-07-18 | Oreal | Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches |
| NZ543486A (en) * | 2005-11-10 | 2009-03-31 | Fonterra Corporate Res And Dev | Compositions of CIS-9, trans-11 conjugated linoleic acid and vaccenic acid and uses thereof |
| US7175835B1 (en) | 2005-12-23 | 2007-02-13 | Conopco, Inc. | Cosmetic emulsions with inorganic sunscreens stabilized with conjugated linoleic acid |
| US7175836B1 (en) | 2005-12-23 | 2007-02-13 | Conopco, Inc. | Oil continuous phase cosmetic emulsions with conjugated linoleic acid |
| US7172754B1 (en) | 2005-12-23 | 2007-02-06 | Conopco, Inc. | Cosmetic emulsions with sunscreens and conjugated linoleic acid |
| US20070189989A1 (en) * | 2006-02-16 | 2007-08-16 | Cantwell Maggie Y | Cosmetic compositions and methods of making and using the compositions |
| ES2283212B1 (es) | 2006-03-31 | 2008-08-16 | Lipotec S.A. | Peptidos sinteticos utiles en el tratamiento de la piel y su uso en composiciones cosmeticas o dermofarmaceuticas. |
| EP2004784B1 (en) * | 2006-04-13 | 2014-01-08 | Stepan Specialty Products, LLC | Process for producing isomer enriched conjugated linoleic acid compositions |
| EP1923066A1 (de) * | 2006-11-08 | 2008-05-21 | Cognis IP Management GmbH | Eine Zusammensetzung enthaltend Rotbuschtee und konjugierte Linolsäure |
| FI20075417A0 (fi) * | 2007-06-05 | 2007-06-05 | Marjo-Riitta Suuronen | Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen |
| HU227970B1 (en) | 2007-07-10 | 2012-07-30 | Egis Gyogyszergyar Nyrt | Pharmaceutical compositions containing silicones of high volatility |
| FR2919501B1 (fr) * | 2007-08-02 | 2010-12-31 | Oreal | Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees |
| FR2920305B1 (fr) * | 2007-09-04 | 2010-07-30 | Oreal | Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles. |
| CN101815502B (zh) * | 2007-09-04 | 2013-10-09 | 欧莱雅 | 橙皮苷和微生物的组合在影响皮肤的屏障功能中的用途 |
| FR2920304B1 (fr) * | 2007-09-04 | 2010-06-25 | Oreal | Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse. |
| FR2942719B1 (fr) * | 2009-03-04 | 2011-08-19 | Oreal | Utilisation de microorganismes probiotiques pour limiter les irritations cutanees |
| US11154535B2 (en) | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
| US10045935B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
| US9987208B2 (en) | 2013-04-04 | 2018-06-05 | Nishizaki Bioinformation Research Institute | Elastin synthesis/regeneration promoting agent |
| WO2016000863A1 (en) | 2014-06-30 | 2016-01-07 | Unilever Plc | Nitrogen containing borane stabilized skin care compositions |
| JP6113133B2 (ja) * | 2014-11-06 | 2017-04-12 | 日本メナード化粧品株式会社 | 幹細胞の未分化状態維持剤及び増殖促進剤 |
| EP3490524B1 (en) | 2016-07-27 | 2021-10-13 | Unilever IP Holdings B.V. | Personal care compositions comprising fatty acid amide derivatives |
| CN114288281A (zh) * | 2021-12-07 | 2022-04-08 | 上海中医药大学附属岳阳中西医结合医院 | 三亚油酸甘油酯在制备预防和/或治疗特应性皮炎的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB548382A (en) † | 1940-12-16 | 1942-10-08 | John Edward Mccormick | Improvements in or relating to toilet creams having cleansing properties |
| US3959491A (en) † | 1974-10-29 | 1976-05-25 | Stiefel Laboratories, Inc. | Stable human skin cosmetic composition containing milk |
| GB1545206A (en) † | 1975-05-27 | 1979-05-02 | Roney Prod & Dev Ltd | Milk-containing cosmetic compositions |
| FR2474310A1 (fr) * | 1980-01-25 | 1981-07-31 | Oreal | Solution stable a l'oxydation de vitamine f et d'huile de jojoba et compositions cosmetiques la contenant |
| DE19537297A1 (de) † | 1995-07-07 | 1997-01-09 | Paerson & Co Gmbh & Co | Kosmetische Präparate mit Wachstumsfaktoren hergestellt aus Milch und Kolostrum von Kühen und Stuten |
| EP0866874B2 (en) * | 1995-11-14 | 2005-06-22 | Loders Croklaan B.V. | Process for the preparation of materials with a high content of isomers of conjugated linoleic acid |
| GB9621630D0 (en) * | 1996-10-17 | 1996-12-11 | Kappa Pharmaceuticals Ltd | Treatment of skin disorders |
| US6019990A (en) * | 1997-11-21 | 2000-02-01 | Natural Nutrition Ltd. As | Conjugated linoleic acid delivery system in cosmetic preparations |
-
1998
- 1998-12-22 GB GBGB9828379.9A patent/GB9828379D0/en not_active Ceased
-
1999
- 1999-12-03 CN CN998162698A patent/CN1217651C/zh not_active Expired - Lifetime
- 1999-12-03 ES ES99963409.0T patent/ES2350900T5/es not_active Expired - Lifetime
- 1999-12-03 AT AT99963409T patent/ATE482749T1/de not_active IP Right Cessation
- 1999-12-03 BR BRPI9916450-7A patent/BR9916450B1/pt not_active IP Right Cessation
- 1999-12-03 WO PCT/EP1999/009589 patent/WO2000037040A1/en active IP Right Grant
- 1999-12-03 EP EP99963409.0A patent/EP1140003B2/en not_active Expired - Lifetime
- 1999-12-03 CZ CZ20012333A patent/CZ302773B6/cs not_active IP Right Cessation
- 1999-12-03 RU RU2001120374/15A patent/RU2253443C2/ru active
- 1999-12-03 PL PL349446A patent/PL200949B1/pl not_active IP Right Cessation
- 1999-12-03 AU AU19720/00A patent/AU767130B2/en not_active Ceased
- 1999-12-03 MX MXPA01006455A patent/MXPA01006455A/es active IP Right Grant
- 1999-12-03 JP JP2000589151A patent/JP4460169B2/ja not_active Expired - Lifetime
- 1999-12-03 CA CA002355633A patent/CA2355633C/en not_active Expired - Lifetime
- 1999-12-03 DE DE69942807T patent/DE69942807D1/de not_active Expired - Lifetime
- 1999-12-13 US US09/459,698 patent/US6287553B1/en not_active Expired - Lifetime
- 1999-12-21 AR ARP990106612A patent/AR021949A1/es active IP Right Grant
-
2000
- 2000-03-06 TW TW089103959A patent/TWI250025B/zh not_active IP Right Cessation
-
2001
- 2001-06-19 ZA ZA200105009A patent/ZA200105009B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL349446A1 (en) | 2002-07-29 |
| CZ20012333A3 (cs) | 2002-01-16 |
| GB9828379D0 (en) | 1999-02-17 |
| MXPA01006455A (es) | 2003-06-06 |
| CA2355633A1 (en) | 2000-06-29 |
| CN1335763A (zh) | 2002-02-13 |
| EP1140003B1 (en) | 2010-09-29 |
| RU2253443C2 (ru) | 2005-06-10 |
| ES2350900T3 (es) | 2011-01-28 |
| TWI250025B (en) | 2006-03-01 |
| JP4460169B2 (ja) | 2010-05-12 |
| CN1217651C (zh) | 2005-09-07 |
| WO2000037040A1 (en) | 2000-06-29 |
| US6287553B1 (en) | 2001-09-11 |
| JP2002532531A (ja) | 2002-10-02 |
| BR9916450A (pt) | 2001-09-04 |
| AU767130B2 (en) | 2003-10-30 |
| EP1140003A1 (en) | 2001-10-10 |
| PL200949B1 (pl) | 2009-02-27 |
| BR9916450B1 (pt) | 2013-06-04 |
| ATE482749T1 (de) | 2010-10-15 |
| ES2350900T5 (es) | 2015-01-15 |
| EP1140003B2 (en) | 2014-11-19 |
| AR021949A1 (es) | 2002-09-04 |
| CA2355633C (en) | 2009-02-10 |
| AU1972000A (en) | 2000-07-12 |
| CZ302773B6 (cs) | 2011-11-02 |
| DE69942807D1 (de) | 2010-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6287553B1 (en) | Skin care composition | |
| EP1200059B1 (en) | Skin care composition | |
| ZA200200552B (en) | Skin care composition. | |
| EP1061896B1 (en) | Cosmetic method of treating skin | |
| JP4896326B2 (ja) | ペトロセリン酸を含有する皮膚保護組成物 | |
| US6042841A (en) | Cosmetic method of treating skin | |
| AU2002220694B2 (en) | Cosmetic method of treating skin |